Shire has discontinued the Phase 2 clinical trial of SHP626 (volixibat), an FDA fast-tracked fatty liver disease drug which was originally licensed by Lumena Pharmaceuticals.
The drug received fast track status nearly two years ago based on the Phase 1 as well as preclinical data.
This is the second drug from the Shire/Lumena deal to have trouble. Shire’s other liver drug, SHP625, also was affected with issues.
Click here to view the entire article.